A study published August 4 in the journal Science and funded by the National Institute of Allergy and Infectious Diseases (NIAID) US, reports that three vaccines with very different modes of action have proved effective in monkeys and satisfy humans conditions for testing.
Researchers at Beth Israel Deaconess Medical Center in Boston and the Walter Reed Army Institute of Research in Silver Spring (Maryland) tested these three vaccines to identify the components of the immune response that cause protection.
It was :
a conventional vaccine based on the inactivated virus;
a vaccine based on a viral DNA fragment;
a vaccine based adenovirus vector (genes Zika are inserted into an adenovirus acting as Trojan horse and infecting cells in order to elicit an immune response).
The three modes of action protecting against infection.
Launch of two human trials
On August 3, the US NIAID announced the launch of a Phase 1 trial of its own vaccine based on DNA. The safety and immune response will be evaluated in 80 healthy volunteers, aged 18 to 35 years recruited from three centers: the National Institutes of Health's Clinical Center in Bethesda, the University of Maryland in Baltimore and the University of Emory in Atlanta.
Inovio Pharmaceuticals Inc. began testing in July, a vaccine based on DNA (for now called "GLS-5700") in a trial in 40 people enrolled in Miami, Philadelphia and Quebec City.
After these tests phases 1 in healthy people 2 phases of tests shall be conducted with populations at risk of infection.
Source :http://www.psychomedia.qc.ca/
Out Of Topic Show Konversi KodeHide Konversi Kode Show EmoticonHide Emoticon